Albert David Faces Financial Challenges Amid Technical Outlook Shift in Pharmaceuticals Sector
Albert David, a microcap pharmaceutical company, has recently experienced a change in evaluation amid a challenging financial quarter for Q3 FY24-25. Key performance metrics have declined, with significant drops in net sales and profit. Despite these issues, the company maintains a low debt-to-equity ratio and fair valuation.
Albert David, a microcap company in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in evaluation, reflecting a shift in its technical outlook. This revision comes amid a backdrop of notable financial metrics and market performance indicators that warrant attention.The company has reported a challenging financial quarter for Q3 FY24-25, with a significant decline in key performance metrics. The operating profit has experienced a contraction at an annual rate of -21.75% over the past five years, indicating difficulties in sustaining growth. Recent figures show a net sales low of Rs 83.08 crore and a PAT of Rs -9.39 crore, marking a substantial drop.
From a technical perspective, the stock has transitioned into a bearish range, with indicators such as Bollinger Bands and KST reflecting this trend. The stock's performance over the past year has also been underwhelming, with returns of -29.46%, which is below the broader market indices.
Despite these challenges, Albert David maintains a low debt-to-equity ratio and an attractive valuation with a return on equity of 10.6. The stock is currently trading at a fair value compared to its peers, suggesting a nuanced position within the market.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
